Review overemphasises benefits and downplays serious harms

BMJ. 2012 Sep 10:345:e5989; author reply e5990. doi: 10.1136/bmj.e5989.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Alendronate / therapeutic use*
  • Bone Density Conservation Agents / therapeutic use*
  • Female
  • Hip Fractures / etiology*
  • Hip Fractures / prevention & control*
  • Humans
  • Osteoporosis / complications*
  • Osteoporosis / drug therapy*

Substances

  • Bone Density Conservation Agents
  • Alendronate